AbbVie Header AbbVie Header

X

Find Drugs in Development News & Deals for Apalutamide

PharmaCompass
API SUPPLIERS
API Suppliers

API Suppliers

US DMFs Filed

US DMFs Filed

CEP/COS Certifications

CEP/COS Certifications

0

JDMFs Filed

JDMFs Filed

0

EU WC

EU WC

Listed Suppliers

Listed Suppliers

API REF. PRICE (USD / KG)
INTERMEDIATES
DOSSIERS // FDF
USA (Orange Book)

USA (Orange Book)

Europe

Europe

0

Canada

Canada

Australia

Australia

South Africa

South Africa

Uploaded Dossiers

Uploaded Dossiers

GLOBAL SALES (USD Million)

U.S. Medicaid

Annual Reports

EXCIPIENTS
PATENTS & EXCLUSIVITIES

USFDA Orange Book Patents

USFDA Exclusivities

0

DIGITAL CONTENT

Blog #PharmaFlow

News

REF STANDARD

EDQM

0

USP

0

JP

0

Other Listed Suppliers

0

SERVICES

0

Details:

Erleada (apalutamide) is an androgen receptor inhibitor which is being investigated for the treatment of patients with hih-risk locally advanced prostate cancer in combination with androgen deprivation therapy.


Lead Product(s): Apalutamide,Androgen Deprivation Therapy

Therapeutic Area: Oncology Product Name: Erleada

Highest Development Status: Phase IIIProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 03, 2024

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

ENV105 (carotuximab) is a endoglin inhibitor which is being evaluated in phase 2 clinical trials in combination with apalutamide for the treatment of castrate-resistant prostate cancer.


Lead Product(s): Carotuximab,Apalutamide

Therapeutic Area: Oncology Product Name: ENV105

Highest Development Status: Phase IIProduct Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 30, 2024

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Erleada® (apalutamide) is an androgen receptor inhibitor indicated for the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC) and for the treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC).


Lead Product(s): Apalutamide

Therapeutic Area: Oncology Product Name: Erleada

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 03, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

APATIDE (generic version of Apalutamide) is a potent androgen receptor (AR) antagonist that selectively binds to the ligand-binding domain and blocks AR nuclear translocation or binding to androgen response elements. Product has been launched in India to treat prostate cancer.


Lead Product(s): Apalutamide

Therapeutic Area: Oncology Product Name: Apatide

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 03, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

ENV105 has been demonstrated to complement standard of care androgen targeted therapy with non-steroidal anti-androgens such as XTANDI® (enzalutamide) and Zytiga® (abiraterone acetate) in limiting therapeutic resistance to these drugs in a previous Phase II trial.


Lead Product(s): ENV-105,Apalutamide

Therapeutic Area: Oncology Product Name: ENV-105

Highest Development Status: Phase IIProduct Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 15, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

ERLEADA® has shown a statistically significant improvement in overall survival with a consistent safety profile, while maintaining patients’ health-related quality of life in both approved indications of mCSPC and non-metastatic castration resistant prostate cancer (nmCRPC).


Lead Product(s): Apalutamide,Androgen deprivation therapy

Therapeutic Area: Oncology Product Name: Erleada

Highest Development Status: Phase IIIProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 14, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Notably, the addition of apalutamide to ADT improved the MFS percentage among the Decipher high-risk patients to a level similar to the percentage among patients classified as Decipher low-to-average-risk.


Lead Product(s): Apalutamide

Therapeutic Area: Oncology Product Name: ARN-509

Highest Development Status: Phase IIIProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 14, 2021

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

RYBREVANT is being studied in a comprehensive clinical development program for people with untreated advanced EGFR-mutated NSCLC, including the Phase 3 MARIPOSA trial studying RYBREVANT in combination with lazertinib.


Lead Product(s): Apalutamide,Androgen deprivation therapy

Therapeutic Area: Oncology Product Name: Erleada

Highest Development Status: Phase IIIProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 01, 2021

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

ERLEADA® is an androgen receptor inhibitor indicated for treatment of patients with non-metastatic castration-resistant prostate cancer. The TITAN study previously demonstrated statistically significant improvement in overall survival in patients receiving ERLEADA® plus ADT.


Lead Product(s): Apalutamide,Androgen deprivation therapy

Therapeutic Area: Oncology Product Name: Erleada

Highest Development Status: Phase IIIProduct Type: Small molecule

Partner/Sponsor/Collaborator: Aragon Pharmaceuticals

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 26, 2021

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

The ACIS study met its primary endpoint of radiographic progression-free survival (rPFS); however, combination treatment did not show significant benefit over the active control ZYTIGA® plus prednisone in key secondary endpoints, including overall survival (OS).


Lead Product(s): Apalutamide,Abiraterone Acetate

Therapeutic Area: Oncology